Digestive Diseases and Sciences

, Volume 55, Issue 3, pp 560-578

First online:

Nonalcoholic Fatty Liver Disease: A Review and Update

  • Jeffrey R. LewisAffiliated withDepartment of Medicine, Center for Liver Diseases, University of ChicagoInternal Medicine
  • , Smruti R. MohantyAffiliated withDepartment of Medicine, Center for Liver Diseases, University of ChicagoSection of Gastroenterology, Center for Liver Diseases, University of Chicago Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The spectrum of nonalcoholic fatty liver disease (NAFLD) ranges from asymptomatic steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. Hepatic steatosis occurs when free fatty acids, released in the setting of insulin resistance and the metabolic syndrome, are taken up by the liver. Additional biochemical insults, including oxidative stress, upregulation of inflammatory mediators, and dysregulated apoptosis, can result in inflammation (producing NASH) and fibrosis. Noninvasive methods (e.g., abdominal ultrasonography) are safe ways to support a diagnosis of hepatic steatosis, but advanced liver histopathologic findings including NASH and fibrosis cannot be identified without pursuing liver biopsy. Recent advances in serologic and imaging methods aim to determine severity of inflammation and fibrosis noninvasively. Currently, therapeutic options for NAFLD are limited to medications that reduce risk factors, but the future holds promise for therapies that might slow the progression of this increasingly prevalent disorder.


Steatosis Steatohepatitis Cirrhosis